. 2022 Mar 30;19(3):146–156. doi: 10.1007/s11897-022-00542-5

Table 3.

Disease progression and mortality of pre-HF patients

Study reference	Source population	Sample size	Age (years)	Gender (male)	Follow-up period	Disease progression	Mortality
Miura M et al. 2014 [42••]	Stage B HF patients	2,380	Not reported	Not reported	Median: 12.7 months	Hospital admission for HF (symptomatic): 1.1%	All-cause death: 1.6%
Pugliese N et al. 2018 [41••]	Stage A or B HF patients	337	Mean ± SD: 54.7 ± 13.7	53.1%	Median (IQR): 22 (30–47) months	Hospitalization for HF (symptomatic): 9.8%	Cardiac death: 0.6% Noncardiac death: 0.9%
Xanthakis V et al. 2016 [38••]	Stage B HF patients	1,637	Not reported	Not reported	Mean: 7 years	New-onset stage C/D HF: Men: 1.14 per 100 person-year Women: 0.63 per 100 person-year	All-cause death: 5.4% Crude annual mortality rate: 0.881 per 100 person-years

Study reference

Source population

Sample size

Age (years)

Gender (male)

Follow-up period

Disease progression

Mortality

Miura M et al. 2014 [42••]

Stage B HF patients

2,380

Not reported

Median: 12.7 months

Hospital admission for HF (symptomatic): 1.1%

All-cause death: 1.6%

Pugliese N et al. 2018 [41••]

Stage A or B HF patients

337

Mean ± SD: 54.7 ± 13.7

53.1%

Median (IQR): 22 (30–47) months

Hospitalization for HF (symptomatic): 9.8%

Cardiac death: 0.6%

Noncardiac death: 0.9%

Xanthakis V et al. 2016 [38••]

Stage B HF patients

1,637

Not reported

Mean: 7 years

New-onset stage C/D HF:

Men: 1.14 per 100 person-year

Women: 0.63 per 100 person-year

All-cause death: 5.4%

Crude annual mortality rate: 0.881 per 100 person-years